文献类型：期刊文献

英文题名：Efficacy and safety of Jueyin granules for patients with mild-to-moderate psoriasis vulgaris: A multicenter, double-blind, randomized, placebo-controlled trial

作者：Sun, Xiaoying[1,2];Wang, Qingyun[1,2];Ji, Yunrun[3];Li, Su[1,2];Zhang, Hongya[4];Zhou, Meng[5];Wang, Sinong[6];Zhou, Dongmei[3];Wang, Jianfeng[4];Liang, Nan[5];Zhou, Wenli[6];Lv, Jingjing;Zhang, Cang[3];Li, Xin[1,2];Li, Bin[1,2]

第一作者：Sun, Xiaoying

通信作者：Li, X[1];Li, B[1];Zhang, C[2]

机构：[1]Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Inst Integrat Med, 110 Ganhe Rd, Shanghai 200437, Peoples R China;[2]Shanghai Acad Tradit Chinese Med, Inst Dermatol, Shanghai 201203, Peoples R China;[3]Capital Med Univ, Beijing Hosp Tradit Chinese Med, Dept Dermatol, 23 Art Museum Back St, Beijing 100010, Peoples R China;[4]Anhui Univ Tradit Chinese Med, Affiliated Hosp 1, Dept Dermatol, Hefei 230031, Anhui, Peoples R China;[5]Guangxi Zhuang Autonomous Reg Inst Dermatol Preven, Nanning 530007, Guangxi, Peoples R China;[6]Gansu Univ Tradit Chinese Med, Affiliated Hosp, Dept Dermatol, Lanzhou 730000, Gansu, Peoples R China

第一机构：Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Inst Integrat Med, 110 Ganhe Rd, Shanghai 200437, Peoples R China

通信机构：[1]corresponding author), Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Inst Integrat Med, 110 Ganhe Rd, Shanghai 200437, Peoples R China;[2]corresponding author), Capital Med Univ, Beijing Hosp Tradit Chinese Med, Dept Dermatol, 23 Art Museum Back St, Beijing 100010, Peoples R China.

年份：2026

卷号：357

外文期刊名：JOURNAL OF ETHNOPHARMACOLOGY

收录：;WOS:【SCI-EXPANDED(收录号:WOS:001617962400001)】；

基金：This study was supported by the National Natural Science Foundation of China (Grant Nos. 82305233, 82575058 and 82374445) , the National Key Research and Development Program of China (Grant Nos. 2018YFC1705302 and 2024YFC3505301) , the CACMS Innovation Fund (Grant No. CI2023C018LH) , Shanghai Oriental Talent Program for Topnotch Project (Grant No. BJWS2024046) , Shanghai Hospital Development Center Foundation (Grant No. SHDC12025132) , the CACM Eaglet Program for Cultivating Young Clinical Talents in Chinese Medicine (Grant No. CYJH2024022) , and the 2025 Shanghai Municipal Health Commission Seed Program for Medical New Technology Research and Translation (Grant No. 2025ZZ1010) .

语种：英文

外文关键词：Psoriasis vulgaris; Blood-heat syndrome; Chinese herbal medicine; Jueyin granules; Clinical trial

摘要：Ethnopharmacological relevance: Psoriasis is an immune-mediated inflammatory skin disease. By more than a decade of clinical validation, Jueyin granules (JYG) have demonstrated multi-target synergistic immunomodulatory and anti-inflammatory effects, offering a characteristic Traditional Chinese Medicine (TCM) therapeutic approach for psoriasis. Aim of the study: To assess the efficacy and safety of oral JYG in treating psoriasis with blood-heat syndrome. Materials and methods: Participants with body surface area (BSA) score less than 10 were allocated to receive JYG or placebo treatment in a 1:1 ratio through central area division and block randomization. The primary outcome is reduction of the psoriasis area severity index (PASI) score and proportion of participants achieving a greater than 50 % reduction in PASI scores (PASI50) at week 8. Results: Between November 2019 and April 2022, 195 participants were randomly assigned to receive JYG (n = 99) or a placebo (n = 96) at five centers. The JYG group demonstrated significantly greater reductions in PASI and BSA scores than the placebo group at week 8 (both P <0.001) and maintained these improvements at week 16 (P < 0.001 and P = 0.005, respectively). By week 8, 51.09 % of participants in the JYG group achieved PASI50, compared to 20.65 % in the placebo group (P < 0.001). However, there were no statistical differences in dermatology life quality index (DLQI), visual analog scale (VAS) scores, or relapse rate. Conclusions: This study provides conclusive evidence that JYG is a safe and effective treatment for patients with mild-to-moderate psoriasis. The current findings support its use as a complementary and alternative therapy for psoriasis.